CRKL as a Lung Cancer Oncogene and Mediator of Acquired Resistance to EGFR Inhibitors: Is It All That It Is Cracked Up to Be?............... 560
M. Ladanyi
Commentary on Cheung et al., p. 608

REVIEW
PI3Kα Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic............. 562
D.A. Fruman and C. Rommel

RESEARCH BRIEFS
Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence................. 573
Précis: An anti-MET monoclonal antibody elicited a 2-year complete response in a patient with metastatic gastric cancer with MET gene polysomy and autocrine HGF production.

A Novel Platform for Detection of CK⁺ and CK⁻ CTCs ............... 580
Précis: An expanded antibody cocktail combined with a microfluidics platform directly incorporating FISH identifies nonepithelial CTCs.
Complete Response of Gastric Cancer with Anti-Met Therapy

March 5, 2007, revealed marked thickening along the lesser signet ring features. A computed tomographic (CT) scan on sided, estrogen receptor/progesterone receptor–positive, HER2-negative metastasis to the gallbladder. The patient had no evidence of residual disease (Fig. 1C). The margins were free of tumor. Postoperatively, the patient underwent a total gastrectomy with D2 lymphadenectomy and polysomy and evidence for an autocrine production of hepatocyte growth factor, the growth factor ligand of Met. A complete response to Met inhibition has efficacy in patients with refractory advanced non–small cell lung cancers.

Preceding CARTherapyWatch, a real-time, kinetic measurement of the cellular response, including objective, long-lasting responses are observed in patients with NSCLC treated with azacitidine and entinostat.

Correction: Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium.

Correction: Forty Years of Translational Cancer Research.

Correction: Drugs, Diagnostic Tests Approved Quickly.

Acknowledgment to Reviewers.